Clinical trial
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877
NCT00471367 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00471367 |
|---|---|
| Title | Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877 |
| Official title | A Phase I, Open-Label, Multi-Center, Dose-Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4877 Administered Twice a Week in Adult Patients With Advanced Solid Malignancies Including Lymphoma |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, NHL, Non-Hodgkin Lymphoma |
| Intervention type | Drug |
| Interventions | AZD4877 |
| Enrollment | 44 |
| Start date | Apr 1, 2007 |
| Completion | Dec 1, 2008 |
| First posted | May 9, 2007 |
| Last update posted | Sep 24, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: